Award
NIH Reporter #5R44CA277917-03
Targeting pancreatic cancer metastases with Targefrin
Recipient
ARMIDA LABS, INC.
Award Amount
$1,088,000.00
Ceiling
$1,088,000.00
Awarded
September 02, 2026
Identifier
5R44CA277917-03
Award for a Phase II SBIR project to develop Targefrin-dimer for pancreatic cancer treatment, funded by the National Cancer Institute with $1,088,000.
Description
This is a Phase II SBIR project focused on manufacturing and IND-enabling studies for pancreatic cancer treatment using Targefrin-dimer. The project is funded by the National Cancer Institute with an award amount of $1,088,000 for fiscal year 2026.